Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition, ...

Passage Bio, Inc., disclosed in an 8-K filing on January 8, 2025, that it has initiated a restructuring plan aimed at ceasing lab operations at its leased laboratory space in Hopewell, New Jersey ...

(RTTNews) - Passage Bio (PASG), a clinical-stage genetic medicines ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA. Read More on PASG: Passage Bio NewsMORE Related Stocks Indices Commodities ...

PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and ...

When we introduced the Nasdaq IPO Pulse a year ago, we said it suggested that U.S. “IPO activity… should remain in an uptrend” as we headed into 2024. Then, when we introduced the Nasdaq ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for ...

A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...